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Abstract:
Over the past decade, the incidence of type 2 diabetes mellitus
(T20M) has increasecl significantly. Evidence has shown tflat a clear
association exists between obesity and diabetes development. This
association has inspired researchers lo explore bariatric surgery as
an option tor diabetes management and possible disease reversal.
Improvement of T20M using Roux-En-Y gastric bypaas (RYGB)
is l1'lought to resuh from a combination of weight loss, decreased
caloric intake, hormonal changes and rearrangement of the gastrointestinal anatomy. Positive outcomes resulting from the procedure
include decreased mortality rates, normalization of HbA1c levels,
decreased dependence on cfiabetic medical.ions, and increased
insulin sensitivity. Gastric bypass, specifically RYGB. appears to be
a promising treatment for T2DM. Due to possible complications and
llmlted research in some populations, treatment should be restricted
to patients with a BMI > 35 with concurrent diabetes. Patients with
dltbetes who qualify shoufd be counseled on the potential benefits
of gastric bypass as a Viable op1ion for diabetes management.

Introduction:
The incidence of type 2 diabetes mellitus (T2DM) is rapidly increasing
worldwide and is stated to be the sixth leading cause of death in the U.S.1
More than 24 million Americans have been diagnosed with diabetes, and
approximately 800,000 new cases arise each year. 2 Between 1995 and
2025, prevalence is expected to increase from 130 million to roughly 300
million.3 Although causation cannot be linked to one specific source, rising
diabetes rates are undeniably associated with the obesity epidemic. In
Western countries, 15-30 percent of the adult population is obese (BMI
> 30). Studies have observed that insulin resistance and diabetes often
follow a large increase in body weight. One such study, the Nurses' Health
Study, found that both men and women who gain 11-19.9 kg after the age
of 18 have 5.5 times the risk of developing T2DM. 3 Furthermore, other
analyses have linked centrally patterned fat distribution with an increased
diabetic risk. Therefore, the development of diabetes depends not only on
ilfestyle choices, but also on genetic components.
Patients with T2DM account for approximately 90 percent of all diabetics. 4 One characteristic commonly seen in T2DM is insulin resistance.
Endogenously, insulin acts to dispose of glucose within the skeletal
muscle as well as to suppress hepatic glucose production. A patient is
considered to have insulin resistance when these endogenous effects
of insulin are decreased. The early stages of T2DM are often marked
by hyperinsulinemia accompanied by accelerated endogenous glucose
production. Hepatic insulin resistance is considered the major contributor
to hyperglycemia in these patients. Cytokines, hormones and nonesterified fatty acids (NEFA} all moderate insulin action and arise in the
adipocytes. A rise in triglyceride stores increases adipocyte size and
alters the ability of insulin to suppress lipolysis. This leads to high circuB
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lating levels of NEFA and glycerol, which cause insulin resistance in the
liver and skeletal muscle. Ectopic fat storage (fat storage in non-adipose
cells) also may intensify insulin resistance. The American Association of
Clinical Endocrinologists suggests T2DM diagnosis be based on the presence of one of three factors:5 Symptoms of diabetes, such as polyuria,
polydipsia and unexplained weight loss, and the causal plasma glucose
concentrations> 200 mg/dl, fasting glucose concentration> 126 mg/dl,
or a two-hour post-challenge glucose concentration ~ 200 mg/dl during a
75 g oral glucose tolerance test.
The 201 OAmerican Diabetes Association (ADA) Standards of Care Guidelines recommend that a physician-coordinated team, including the pharmacist, oversee the management of diabetes and provide the patient with
proper medical nutrition therapy and diabetes self-management education. 6
For glucose management, the ADA recommends self-monitoring of blood
glucose (if on insulin), testing HbA1c two to four times yearly dependent on
patient's blood glucose control, and initiating metformin therapy and lifestyle
changes at the time of diagnosis with medicinal therapy augmentation as
needed. Furthermore, diabetes leads to accelerated development of micro
and macrovascular disorders. Cardiovascular disease is the leading cause
of morbidity and mortality among diabetic patients. The guidelines therefore
indicate that blood pressure control, lipid management and aspirin therapy as
needed, in addition to proper screening and treatment for coronary heart disease, nephropathy, retinopathy and neuropathy, are important components
of care. Finally, for the first time, the ADA has included bariatric surgery as a
treatment option for those patients with a BMI > 35 and concurrent T2DM in
their 201 Oguidelines.
Bariatrlc surgery
Due to the evident association between obesity and diabetes, many researchers are exploring the option of bariatric surgery for diabetes management and possibly disease reversal. Currently, four types of gastric bypass
are generally performed. The adjustable gastric band (AGB) is a band that
can be placed around the top of the stomach to form a smal I pouch. 7 Band
size is controlled by modifying the amount of saline solution in the band in
order to increase or decrease the size of the band's circular balloon, thereby
altering stomach outlet size. In Roux-en-Y gastric bypass (RYGB), digestive
tract size is reduced through bypassing most of the stomach, duodenum
and upper intestine. This not only limits food intake to that which can fit in a
small pouch, but also decreases gastrointestinal absorption. Biliopancreatic
diversion with a duodenal switch (BPD-DS) consists of a reduction in stomach size to reduce food intake, a redirection of food away from the small
intestine to drastically decrease absorption, and a redirection of bile and
digestive juices to impair digestion. Typically, BPD-DS results in the most
weight loss but also has the highest risk of long-term complications because
of the malabsorption that results. Lastly, vertical sleeve gastrectomy (VSG),
one of the three components of BPD-DS, drastically reduces stomach
size as mentioned previously. This size reduction also may decrease the
amount of ghrelin produced, reducing hunger to a greater extent than the
lap band operation and aiding in patient success.
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How it works
Since the 1980s, research has been conducted to assess the efficacy of
using gastric bypass surgery for the treatment of T2DM, and, as previously stated, the ADA has recently included gastric bypass as a therapeutic option for T2DM within their guidelines.2•6 Scientists hypothesized
that the excessive amount of weight loss resulting from the surgery may
diminish the symptoms of T2DM. It has been verified that surgery is the
most effective way to produce sustained and substantial weight loss in
patients. 8 The weight reduction strategies that have been used include
gastric restriction via the reduction of stomach volume and intestinal
malabsorption due to the shortening of the small intestine and decreasing the surface area available for nutrient absorption. 9
One of the main surgeries currently being investigated that has shown the
most promising results is RYGB. During this surgery, the stomach is divided into two sections, where a small stomach pouch (15-30 ml in volume)
is formed in the upper part of the stomach by using surgical staples or a
gastric band. 2 This small pouch is directly connected to the middle portion
of the jejunum, thus bypassing the lower part of the stomach, the duodenum and part of the jejunum. Gastric juices, bile and pancreatic enzymes
continue to flow from the lower part of the stomach and duodenum through
the small intestines and meet the other channel at a Y-shaped junction.
Improvement of T2DM using RYGB is thought to be a result of a
combination of weight loss, decreased caloric intake, hormonal changes
and rearrangement of gastrointestinal anatomy. 2 The amount of overall
weight loss does not prove to be the primary mechanism of treatment
for diabetes because the resolution of diabetes occurs within days after
surgery, prior to the majority of the weight loss. Complete eradication
of the disease, however, is seen more frequently in those patients who
lose more weight. It has been observed that the decreased caloric intake
resulting from RYGB may help with short-term glycemic control, but
overall resolution of T2DM cannot be accounted for due to decrease
in caloric intake. Hormonal changes are thought to be one of the main
reasons for this possible success in T2DM. RYGB has shown to result in
increased levels of GLP, Peptide YY (PYY), adiponectin and decreased
levels of GIP, acylation-stimulating protein (ASP), leptin, and ghrelin.
These hormones have a major impact on the function of the GI tract and,
when altered due to RYGB, may lead to many of the positive effects of
the surgery (table 1).

Gastrolntestlnal

Benefits
Diabetes often is a life-altering and life-defining disease that many
individuals have difficulty managing. Gastric bypass surgery can be
very beneficial for some patients that have had difficulty in achieving
adequate diabetes control. Positive outcomes resulting from the surgery
include decreased mortality rates, normalization of HbA1c levels,
decreased dependence on diabetic medications, and increased insulin
sensitivity. A study including 608 morbidly obese patients that were
followed for 14 years post-gastric bypass operation reported an average
excess weight loss of 49 percent. 9 0f the 608 patients, 330 had either diabetes (n= 165) or impaired glucose tolerance (n= 165) at baseline. At the
end of the study, 82 percent of those with T2DM had normal HbA1c levels. Another study including 232 morbidly obese patients, all with T2DM,
was conducted to assess long-term mortality rates. It was found that the
mortality rate of the control group was significantly higher (P<0.0003)
than the surgical group. The number of cardiovascular deaths was the
major variant between the two groups. By decreasing mortality rates and
HbA 1c levels, a diabetic patient may have a prolonged and better quality
of life.
Once diagnosed with diabetes, it is rare that there will be a day that a
patient will go without taking a pill again. Gastric bypass has shown to
minimize the number of medications needed for a diabetic patient, which
will help with patient compliance issues and allow for simpler medication therapy. 2 In general, RYGB shows a reduction in the dependence
on diabetic medication of 80-98 percent of patients for up to 14 years
of follow-up. Surgery is more effective than medicinal treatment alone
for improving diabetes for long-term effects. A study comparing 154
morbidly obese type 2 diabetics that had gastric bypass surgery to 78
control patients showed that 87 percent of the control group required
medication intervention after nine years of follow-up. After 6.2 years
of follow-up, medication intervention required for the surgery group fell
from 31 percent to 9 percent. Another study, which included 378 type 2
diabetic patients that underwent weight reduction surgery, 72 of which
were medicated, showed that there was a significant reduction in blood
sugar level from 9.1 mmol/L (preoperative) to 6.6 mmol/L (postoperative)
with a P=0.005. 8 Of the 72 patients who were medicated, 36 patients
had stopped all medication for diabetes, and none had an increase in
dose post-operation. There was a 75 percent reduction in patients that

Table 1·Effect of RYGB on Gastrointestinal Tract (GIT) Hormones2
Hormone

Increase/Decrease in Hormone
following RVGB

Endogenous Effect

GLP-1

Increase

Acts to suppress glucagon, reduce glucose production by the liver,
increase insulin production, slow gastric emptying, and enhance satiety

GIP

Decrease

Stimulates insulin release and synthesis

ASP

Decrease

Increased glucose uptake and fatty acid esterification

Ghrelin

Decrease

Appetite-stimulating hormone

pyy

Increase

Decreases food intake by inhibiting gut motility

Adiponectin

Increase

Stimulates glucose utilization and fatty acid oxidation in skeletal muscle

lncretin

Decrease

Secreted after meals to enhance insulin secretion
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required insulin after the operation. Sixty-nine percent of all patients
that underwent RYGB surgery as the weight reduction surgery were
off all medications post-operation (P<0.0001 ). There was no significant
relationship between the amount of weight loss and change in diabetic
status. While a complete reversal of diabetes may be life-changing for
an individual, a reduction in diabetes medication use in those who do not
achieve complete reversal also can be very beneficial. Currently available studies have generally shown a decreased need for medications
following gastric bypass surgery for the diabetic patient. More studies
need to be performed to further confirm and more accurately assess the
benefits and mechanisms surrounding this matter.
One of the most challenging issues for diabetic patients is glucose control. It is a constant struggle for doctors and pharmacists to counsel patients on ways to minimize fluctuations in glucose levels. Gastric bypass
may be a beneficial option for patients who struggle to maintain normal
glucose levels. After gastric bypass surgery, a normalization of glucose
metabolism is often seen within weeks of surgery. 2 Long-term effects are
better seen within two to five years post-operation. In a trial investigating
4,047 subjects treated for obesity, 72 percent of the patients surgically
treated recovered from T2DM within two years of surgery, compared to
only 21 percent of the control group.
Gastric bypass has shown its best effects in its long-term treatment of
T2DM. A resolution rate of diabetes is between 83-85 percent in the long
term for gastric bypass surgery. 8 RYGB is more effective for the treatment of T2DM in patients with a milder form and a shorter duration of the
disease. 2 Patients who do not experience significant improvement from
the surgery tend to be older. Unlike insulin sensitivity, B cell function
improvement is more closely related to duration of diabetes rather than
weight loss. 9 While gastric bypass surgery has proven to show many
benefits for the treatment of T2DM, these benefits should be weighed
against the risks of surgery before using this method in any patient. Also,
the characteristics of the patient must be considered in determining if
qualifications for this surgery are met, including obesity and BMI criteria.

cial impairment. Surgery should only be considered after candidates have
attempted weight reduction for at least six months and have failed.
Following RYGB, the risk of developing vitamin and mineral deficiency
is significantly increased. RYGB can lead to decreased levels of vitamin
812, fol ate, iron and calcium either through malabsorption or insufficient
intake.11 Supplementation of these specific vitamins is vital following
RYGB surgery.

Cost Analysis
As previously mentioned, comprehensive medical costs for RYGB
without insurance are an estimated $26,000. 10 Insurance coverage varies,
and, if coverage is provided, it normally does not cover the entire cost
of surgery. Comparatively, a 201 Ostudy employed a Cost of Diabetes
Model to estimate the U.S. economic burden related to diabetes. 12 The
study analyzed information from peer-reviewed literature, government
statistics and national survey, and medical claim databases. The average
annual cost per patient standardized to 2007 dollar amounts was $2,864
for undiagnosed diabetes and $9,677 for diagnosed T2DM. As a reference, the median age of diagnoses for T2DM was 57 with annual costs
increasing with age. Depending on quality of insurance coverage, length
of life, age of diagnosis and success of surgery in treatment of symptoms,
gastric bypass offers potentially great long-term cost savings, although the
actual magnitude of these savings is still to be determined. More costeffectiveness studies need to be completed to fully and more adequately
compare the costs of bariatric surgery as treatment for T2DM versus the
current standard of care.

Risks
Along with any surgery comes risk of treatment, possible complications
and death, in addition to potential hardships from expenses and medical
bills. Figures show that there is less than 1 percent risk of mortality for
patients undergoing RYGB, and a risk of complications range from less
than 1oto 20 percent. 8 Medical bills for RYGB, including hospital stays,
anesthesia, lab costs and surgeon fees, costs approximately $26,000
without health insurance. 10 Insurance coverage varies from plan to plan,
but bariatric surgery is frequently not covered in full, if at all.

Effect on Drug Absorption
Data examining the effect of bariatric surgery on drug absorption is lacking. A recent review of the literature suggests that, although there is little
known, the effect of bariatric surgery on drug absorption appears to be
drug-specific. 13 In some cases, substantial reductions in drug absorption
may occur, which may be temporally associated with the need for dosage
adjustment. Overall, evidence for decreased drug absorption was found
in 15 of 22 studies involving jejunoileal bypass, one of three studies of
gastric bypass/gastroplasty, and none in the one study examining biliopancreatic diversion. Specifically, multiple reports described decreased
absorption for anti-rejection drugs (cyclosporine and tacrolimus}, thyroxine, phenytoin and rifampin. Single instances of diminished absorption
of ethosuximide, amoxicillin, macrodantin, tacrolimus, sulfisoxazole and
hydrochlorothiazide were reported. Conflicting evidence was present for
ethambutol, digoxin and oral contraceptives. Further study is needed
to assess the degree of malabsorption specific to each medication and
whether there are major differences among procedure types that exist. 13

Complications of these operations include bleeding, infection and blood
clots that can move to the heart or lungs.7 Later problems, such as
malnutrition, strictures and hernias, also may occur. Studies suggest that
up to 1Opercent of patients receiving bariatric surgery may experience
inadequate weight loss or may regain much of the weight that is initially
lost. Experts recommend that these procedures be performed only on
adolescents that are extremely obese (typically with BMI greater than
40), have reached their adult height (usually 13 or older for girls and 15 or
older for boys), and have serious weight-related health problems, such as
T2DM, sleep apnea, heart disease, or significant functional or psychoso-

Conclusion
Gastric bypass, specifically RYGB, appears to be a promising treatment
for T2DM. RYGB not only slows progression of the disease, but also offers
potential disease resolution. The average long-term diabetes resolution
rate for those who undergo surgery is an impressive 83-85 percent, which
considerably improves quality and duration of life, achieved through a
significant reduction in diabetes-associated complications. Also, it is
suspected that a cost savings will be incurred through medication reduction or cessation. Although RYGB has shown great success, studies have
revealed better outcomes in younger individuals newer to diagnosis with a
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milder form of the disease. RYGB as a treatment for T2DM should be restricted to patients with a BMI > 35 with concurrent diabetes, due to potential complications of surgery and limited research support beyond use
in other populations. Patients should be able and willing to exhibit high
levels of compliance to current medication therapy, as physician visits
and daily vitamin supplementation will be required following surgery. It
is vltal that patients comply with continual follow-up visits to promote
optimal results. Much focus should be placed on these parameters when
electing candidates for surgery. This strategy has grabbed the attention of many health care professionals, and with 30 years of supporting
research, gastric bypass now has been included in clinical guidelines as
an appropriate treatment option for some T2DM patients.
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